REVALESIO CORP

Profile

Company Names

REVALESIO CORP

Addresses

1202 EAST D ST, TACOMA, WA 98421

1202 E. D ST, TACOMA, WA 98421

1200 EAST D STREET, TACOMA, WA 98421

1200 E. D ST, TACOMA, WA 98421

Phone Numbers

253 922 2600

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS, BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$103,398,607.00

Number of Funding Rounds:

6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2022-05-25 
$38,877,508.00 
$40,300,000.00 
$1,422,492.00 
Equity, Debt 
5
2020-07-08 
$20,371,187.00 
$26,771,147.00 
$6,399,960.00 
Equity 
4
2018-06-15 
$6,000,000.00 
$12,002,400.00 
$6,002,400.00 
Equity, Debt 
3
2016-06-23 
$13,999,912.00 
$13,999,912.00 
$0.00 
Equity 
2
2014-04-21 
$13,500,000.00 
$40,000,000.00 
$26,500,000.00 
Equity 
1
2012-06-06 
$10,650,000.00 
$20,000,000.00 
$9,350,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
TROY 
 
ALSTEAD 
DIRECTOR
GREG 
 
ARCHAMBEAU 
EXECUTIVE OFFICER
KARL 
 
BANDLIEN 
DIRECTOR
TOM 
 
BUMOL 
DIRECTOR
BRUCE 
 
BUSKIRK 
EXECUTIVE OFFICER
PATRICK 
 
CARUANA 
DIRECTOR
CHRIS 
 
FIBIGER 
DIRECTOR
LIAM 
 
GALLACHER 
DIRECTOR
WILLIAM 
 
GALLACHER 
DIRECTOR
MATT 
 
IRELAND 
DIRECTOR
JAMES 
 
NORDSTROM 
DIRECTOR
JIM 
 
NORDSTROM 
DIRECTOR
ERIC 
 
RUSSELL 
DIRECTOR, EXECUTIVE OFFICER
MARSHA 
 
RUSSELL 
DIRECTOR
JEFFREY 
 
SMITH 
DIRECTOR
ALDEN GLOBAL EMERGING MARKETS FUND I, L.P.   |  ALDEN GLOBAL EMERGING MARKETS FUND I, LTD.   |  ALDEN GLOBAL DISTRESSED OPPORTUNITIES FUND (CAYMAN), L.P.   |  RAMIUS GLOBAL CREDIT FUND LTD   |  VERGEPOINTE CAPITAL FUND VIII, L.P.   |  MCG FINANCIAL MANAGEMENT, LLC   |  VERGEPOINTE CAPITAL FUND X, LP   |  STARBOARD VALUE + OPPORTUNITY S LLC   |  VERGEPOINTE CAPITAL FUND VII, LP   |  VERGEPOINTE CAPITAL FUND XI, LP   |  STARBOARD VALUE + OPPORTUNITY FUND LP   |  VERGEPOINTE CAPITAL FUND, XII LP   |  VERGEPOINTE CAPITAL FUND XIV, LP   |  MIDLAND STATES BANCORP, INC.   |  STARBOARD LEADERS FUND LP   |  REVIONICS INC   |  VERGEPOINTE CAPITAL FUND XVII, LP   |  STARBOARD LEADERS OFFSHORE FUND LP   |  HARPETH FINANCIAL SERVICES, LLC   |  VERGEPOINTE CAPITAL FUND XVIII, LP   |  VERGEPOINTE CAPITAL FUND XIX, LP   |  VERGEPOINTE CAPITAL FUND XX, LP   |  STARBOARD LEADERS SELECT FUND LP   |  RIPTIDE AUTONOMOUS SOLUTIONS, LLC   |  STARBOARD LEADERS SELECT OFFSHORE FUND LP   |  KKR SPECIAL SITUATIONS (TE) FEEDER II L.P.   |  KKR SPECIAL SITUATIONS (EEA) FUND II L.P.   |  KKR SPECIAL SITUATIONS (DOMESTIC) FUND PRIVATE INVESTORS II L.P.   |  KKR SPECIAL SITUATIONS (DOMESTIC) FUND II L.P.   |  PROPETRO HOLDING CORP.   |  CATAPULT HEALTH, LLC   |  VERGEPOINTE CAPITAL FUND XXI, LP   |  THEMAC RESOURCES GROUP LTD   |  VERGEPOINTE CAPITAL FUND XXII, LP   |  ALDER BIOPHARMACEUTICALS INC   |  REVALESIO CORP   |  CORTRUST BANK NATIONAL ASSOCIATION   |  VERGEPOINTE CAPITAL FUND XXIII LP   |  STARBOARD VALUE + OPPORTUNITY FUND L LP   |  VYPE MEDIA, LLC   |  CANNON WORKSPACE, LLC   |  GENZ HOLDINGS INC.   |  VERGEPOINT CAPITAL FUND XXIV LP   |  MEMORIAL HOUSTON SURGERY CENTER, LLC   |  VARSITY HYPE, INC.   |  STARBOARD X FUND LP   |  LIQUID RARITY EXCHANGE LLC   |  LIGHTMATTER, INC.   |  WHITE PLAINS PARTNERS, LLC   |  ZYMEWORKS INC.   |  JUNCTION HILL PARTNERS, LLC   |  XL BATTERIES, INC.   |  KKR ASSET-BASED FINANCE PARTNERS II (EEA) SCSP   |  CARDINAL CREEK PARTNERS, LLC   |  TILT FIVE, INC.   |  RED TAIL RAVINE PARTNERS, LLC   |  BLUE JAY BEND PARTNERS, LLC   |  OGEECHEE RESERVE PARTNERS, LLC   |  PIGEON POINT PARTNERS, LLC   |  SPARROW RUN PARTNERS, LLC   |  FALCON FORGE PARTNERS, LLC   |  APOGEE ACQUISITION SPONSOR LLC   |  TEXAS HEALTH SURGERY CENTER ROCKWALL, LLC   |  TEXAS HEALTH SURGERY CENTER FORNEY, LLC
JANE 
 
TAYLOR 
DIRECTOR
BERT 
 
VAN DEN BERGH 
EXECUTIVE OFFICER, DIRECTOR
SCOTT 
 
WALCHECK 
DIRECTOR
SCOTT 
 
WALCHEK 
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D/A
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2022-05-25 
D/A
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2022-05-25 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2022-05-25 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2020-07-08 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2018-06-15 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-06-23 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-04-21 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-06-06 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#